ADMP
Adamis Pharmaceuticals Corp
CEO
Dennis Carlo
Employees
17
Industry
Pharmaceutical Preparation Manufacturing
adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
Loading...
Open
0.75
Mkt cap
7.3M
Volume
119K
High
0.79
P/E Ratio
-0.08
52-wk high
21.70
Low
0.75
Div yield
N/A
52-wk low
0.45

During Friday's session, 157 stocks hit new 52-week lows. Among the notable companies were Corteva, American Rebel Holdings, Mullen Automotive, and BNY Mellon Strategic. The stocks that created new 52-week lows on Friday included Avangrid, SolarEdge Technologies, Etsy, UGI, Concentrix, Hawaiian Electric Indus, Equity Commonwealth, Forward Air, Cracker Barrel Old, Petco Health and Wellness, JinkoSolar Holding Co, Olaplex Hldgs, Frontier Group Holdings, Impinj, Safehold, Monro, 3D Sys, TDCX, Everbridge, Silk Road Medical, Cassava Sciences, 23andMe Holding, Wolverine World Wide, Avidity Biosciences, Boston Omaha, John Hancock Premium Div, BioLife Solns, Seres Therapeutics, American Well, Materialise, BNY Mellon Strategic, Southland Holdings, Funko, Fate Therapeutics, Citizens Financial Servs, American Lithium, Emergent BioSolutions, PetMed Express, Sutro Biopharma, Hippo Holdings, Largo, Omega Therapeutics, System1, Benson Hill, Eaton Vance Municipal, Vor Biopharma, Star Hldgs, Origin Mat, Joint, NanoString Technologies, Codexis, ContextLogic, Akoustis Technologies, Cano Health, GeneDx Hldgs, Electrovaya, Kezar Life Sciences, ProPhase Labs, Alaunos Therapeutics, Chimerix, Electriq Power Holdings, DZS, Streamline Health Solns, Eargo, Intercure, Prime Number Acquisition, REE Automotive, TD Hldgs, Carmell Therapeutics, Neuronetics, Kaixin Auto Hldgs, Crown Crafts, Airgain, Ohmyhome, Singular Genomics Sys, First Seacoast Bancorp, Sarcos Technology, Coya Therapeutics, Otonomo Technologies, CareCloud, Aterian, PAVmed, Orgenesis, CalAmp, Imperial Ptrl, Fitell, LQR House, Iridex, OMNIQ, Safeguard Scientifics, Lichen China, Origin Agritech, Atreca, Sunlight Finl Hldgs, Yunji, MediaCo Holding, Trio Petroleum, Cineverse, Lucy Scientific Discovery, Remark Hldgs, Shuttle Pharmaceuticals, Hempacco, Finch Therapeutics Gr, Visionary Education Tech, Marpai, Ontrak, Nogin, Adamis Pharmaceuticals, China Jo-Jo Drugstores, ABVC BioPharma, Fangdd Network Group, SeaStar Medical Holding, Yoshiharu Global, Universe Pharmaceuticals, Redhill Biopharma, Jiuzi Hldgs, Power REIT, Soligenix, Eightco Holdings, JanOne, Avalo Therapeutics, Yield10 Bioscience, Aditxt, Salarius Pharmaceuticals, China Pharma Holding, OpGen, Akanda, Harbor Custom Dev, Biocept, NeuBase Therapeutics, Ucommune International, INVO Bioscience, Esports Entertainment, American Rebel Holdings.
Portfolio Pulse from Benzinga Insights
August 11, 2023 | 6:01 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.